Category: Alzheimer’s Disease (Page 7)

May 20, 2013

Rules of Engagement in Drug Development

The first rule of patient engagement is that patients come first! Even though patient engagement currently occurs across a wide range of venues through a wide range of mechanisms, this rule may not always be considered. Appropriate types of engagement need to be implemented at critical times in the drug development process in order to generate meaningful, useful information from the patient perspective. The purpose of this issue panel is to present the patient view on how to get patient engagement right. The goal of this panel is to identify principles for meaningful patient engagement during medical product development.
May 13, 2013

Tweets Do Tell: Alzhemier’s Not a High Priority for Research Funding

An article by Cynthia Bens, Alliance vice president of public policy
May 1, 2013

NIH ADRD Conference

At this conference, leading neuroscientists, physicians, and public and private stakeholders will discuss key challenges and special opportunities in research on Alzheimer’s disease-related dementias.
February 7, 2013

Statement on FDA Draft Guidance for Alzheimer’s Drug Development

Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) coalition released a statement in response to guidance from the U.S. Food and Drug Administration (FDA) on the development of drugs for Alzheimer’s Disease.
December 18, 2012

Recommendations for Advancing Alzheimer’s Interventions

This week the Alliance for Aging Research and the U.S. Administration on Aging (AoA) released a new white paper titled Translating Innovation to Impact: Evidence-based interventions to support people with Alzheimer's disease and their caregivers at home and in their communities.
November 29, 2012

FDA/AD Allies Meeting on Combination Therapy Development

To address critical issues in the development of new Alzheimer’s disease treatments, the Accelerate Cure/Treatments for Alzheimer’s Disease (ACT-AD) coalition and the Critical Path Institute will co-host the fifth-annual FDA/AD Allies Meeting. This annual meeting sponsored by ACT-AD brings together leaders in Alzheimer’s drug development from the patient advocacy community, federal health and regulatory agencies, academic research, and the private sector for focused discussions on key issues surrounding the development and regulation of Alzheimer’s drugs and therapies.
June 1, 2012

Translating Innovation to Impact: Evidence-based interventions to support people with Alzheimer’s disease and their caregivers at home and in the community

This white paper presents the findings and recommendations from a review of the state of the art non-pharmacological treatments and…
June 1, 2012

Translating Innovation to Impact: Pre-reads

On June 28, 2012 the Alliance for Aging Research and its project partner the U.S. Administration on Aging (AoA), convened Translating Innovation to Impact, a one-day working meeting to review the state of research into evidence-based interventions to help people with Alzheimer’s remain healthy and independent in the community while reducing the stress on their caregivers. This document provides the agenda and pre-reads for that important meeting.
February 9, 2012

Big Boost for Alzheimer’s

This week’s press event announcing an immediate $50 million infusion of NIH funding to Alzheimer’s research—along with commitments to include an additional $80 million in research dollars and $26 million in services and supports in the President’s FY 2013 budget—was monumental on a number of fronts.
February 1, 2012

Ready for Prime Time

Thought Experiment: Biomarkers of Alzheimer’s disease are ready for widespread use in clinical trials.